Loading…
Fulcrum Therapeutics, Inc. is projected to rise to $7.17 by 2027, a +6% move from its current price of $6.78. FULC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.56 | $6.78 | $7.01 | -0.01% |
| May 30 | $6.46 | $6.78 | $7.11 | -0.01% |
| May 31 | $6.39 | $6.78 | $7.19 | -0.02% |
| Jun 1 | $6.34 | $6.78 | $7.25 | -0.02% |
| Jun 2 | $6.29 | $6.78 | $7.31 | -0.03% |
| Jun 3 | $6.24 | $6.78 | $7.36 | -0.04% |
| Jun 4 | $6.20 | $6.78 | $7.41 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.20 | $6.78 | $7.41 | -0.04% |
| Week 2 | $5.97 | $6.77 | $7.68 | -0.09% |
| Week 3 | $5.80 | $6.77 | $7.90 | -0.13% |
| Week 4 | $5.66 | $6.77 | $8.09 | -0.17% |
| Week 5 | $5.54 | $6.77 | $8.26 | -0.22% |
| Week 6 | $5.44 | $6.76 | $8.41 | -0.26% |
| Week 7 | $5.34 | $6.76 | $8.56 | -0.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize.
Fulcrum Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fulcrum Therapeutics, Inc. trades at $6.57 per share and has a market capitalization of $437.78M, with a ranking of 3140 by market cap.
The current price and position sit within a near-term technical setup that shows bearish momentum, reflected by the RSI of 40 and a price trading below near-term averages. The stock’s 30-day range spans from $5.20 to $8.29, with a support level at $5.91 and resistance at $8.29. The 30-day volatility is elevated, indicating notable price movement potential.
A major floor 32.0% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
The nearest ceiling, 22.3% above — a clean break opens room to run.
A major ceiling 73.0% above — clearing it would confirm fresh momentum.
Key FULC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FULC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.61 | Buy | $6.65 | Buy |
| MA 10 | $6.61 | Buy | $6.67 | Buy |
| MA 20 | $6.84 | Sell | $6.86 | Sell |
| MA 50 | $7.25 | Sell | $7.41 | Sell |
| MA 100 | $8.52 | Sell | $8.04 | Sell |
| MA 200 | $8.80 | Sell | $8.14 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.26 | Neutral |
| Stoch RSI (14) | 95.89 | Sell |
| CCI (20) | -12.86 | Neutral |
| Williams %R (14) | -35.07 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -3.28 | Sell |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 64.93 | Neutral |
| TRIX (15) | -0.55 | Sell |
| Awesome (5,34) | -0.64 | Sell |
| Ultimate (7,14,28) | 48.52 | Neutral |
| Momentum (10) | -0.18 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 6.76 | Buy |
| ADX (14) | 16.45 | Neutral |
| ATR (14) | 0.21 | Info |
The near-term technical picture is bearish, with RSI at 40. The stock sits below the 50-day and 200-day moving averages, where the SMA50 is $7.28 and the SMA200 is $8.80. Key levels to watch are support at $5.91 and resistance at $8.29. The 30-day range is $5.20–$8.29, highlighting a broad trading band and elevated volatility (annualized volatility of 70%).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.91 | $6.78 | $9.19 | 0% | Neutral | |
| $5.56 | $7.17 | $9.87 | +6% | Neutral | |
| $6.58 | $8.79 | $12.63 | +30% | Bullish | |
| $7.82 | $10.75 | $15.97 | +59% | Bullish | |
| $7.73 | $10.90 | $16.65 | +61% | Bullish | |
| $8.12 | $11.72 | $18.36 | +73% | Bullish | |
| $8.12 | $12.00 | $19.21 | +77% | Bullish | |
| $7.78 | $11.73 | $19.16 | +73% | Bullish | |
| $8.34 | $12.84 | $21.35 | +89% | Bullish | |
| $10.05 | $15.77 | $26.68 | +133% | Bullish | |
| $10.99 | $18.85 | $34.22 | +178% | Bullish | |
| $21.40 | $43.02 | $86.53 | +535% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.91 | $6.78 | $8.02 | +0.00% |
| June 2026 | $5.81 | $6.85 | $8.31 | +1.07% |
| July 2026 | $5.65 | $6.74 | $8.31 | -1.62% |
| August 2026 | $5.79 | $6.96 | $8.69 | +3.31% |
| September 2026 | $5.88 | $7.12 | $8.97 | +2.19% |
| October 2026 | $5.65 | $6.88 | $8.75 | -3.36% |
| November 2026 | $5.56 | $6.81 | $8.74 | -0.93% |
| December 2026 | $5.78 | $7.11 | $9.19 | +4.39% |
Click any year to see its month-by-month FULC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, FULC could reach as high as $9.19, with a base case around $6.78 and support toward $5.91 — roughly 0% from $6.78. A consolidation phase looks the most probable path here.
Expect FULC to range from $5.56 to $9.87 through 2027. The $7.17 average target implies a +6% move from current prices. That is up +6% on the projected 2026 average. Price action looks broadly range-bound.
The FULC price prediction for 2028 points to an average of $8.79 (low $6.58, high $12.63) — a potential gain of +30% on today's $6.78. Buyers look set to stay in control over this stretch.
In 2029, FULC is projected to trade between $7.82 and $15.97, averaging $10.75 — a potential gain of +59% from today's $6.78. That is up +22% on the projected 2028 average. Momentum favours further upside here.
Fulcrum Therapeutics, Inc.'s 2030 outlook centres on $10.90, within a $7.73 to $16.65 range. That is up +1% on the projected 2029 average. That marks a +61% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, FULC could reach as high as $18.36, with a base case around $11.72 and support toward $8.12 — roughly +73% from $6.78. Momentum favours further upside here.
Expect FULC to range from $8.12 to $19.21 through 2032. The $12.00 average target implies a +77% move from current prices. That is up +2% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The FULC price prediction for 2033 points to an average of $11.73 (low $7.78, high $19.16) — a potential gain of +73% on today's $6.78. Momentum favours further upside here.
In 2034, FULC is projected to trade between $8.34 and $21.35, averaging $12.84 — a potential gain of +89% from today's $6.78. That is up +9% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Fulcrum Therapeutics, Inc.'s 2035 outlook centres on $15.77, within a $10.05 to $26.68 range. That is up +23% on the projected 2034 average. That marks a +133% change versus current levels. Momentum favours further upside here.
By 2040, FULC could reach as high as $34.22, with a base case around $18.85 and support toward $10.99 — roughly +178% from $6.78. Buyers look set to stay in control over this stretch.
Expect FULC to range from $21.40 to $86.53 through 2050. The $43.02 average target implies a +535% move from current prices. That is up +128% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in FULC today (≈ 147.492625 FULC) could be worth
$6,345.13
+$5,345.13 (+535%) by 2050 · US Dollar
Based on the average projected FULC price of $43.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FULCwould be worth at today's price.
$1,000 invested in FULC on May 27, 2025 (≈ 157.480317 FULC) would be worth
$1,067.72
+$67.72 (+6.8%) today · 1.07× · US Dollar
Based on a FULC entry price of $6.35 vs. today's $6.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.35 | $1,067.72 | +6.8% |
| 1 month ago | $7.72 | $878.24 | -12.2% |
| 3 months ago | $8.73 | $776.63 | -22.3% |
| 6 months ago | $10.94 | $619.74 | -38.0% |
| 1 year ago | $6.35 | $1,067.72 | +6.8% |
| All time (5.0y) ago | $8.74 | $775.74 | -22.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FULC forecast.
Our base-case forecast reaches $14.00 around 2035.
Implied market cap at $14.00: $932.87M
The year-by-year forecast shows a path from Neutral to Bullish over time, with meaningful upside in the later years. The 2026 forecast is min $5.91, avg $6.57, max $9.00 (ROI 0, sentiment Neutral). By 2028 the average is $8.47 with a 28.9% ROI and Bullish sentiment, rising further to an average of $10.42 in 2029 and 2030 with the same 58.6% ROI and Bullish sentiment.
In 2031–2035 the averages range from $11.31 to $15.14 with ROIs from 72.2% to 130.5% and Bullish sentiment. The forecast progresses to $17.88 average in 2040 (ROI 172.1%) and ultimately to $40.98 average in 2050 (ROI 523.8%), all with Bullish sentiment. These are estimates, not guarantees, and the numbers reflect a wide potential trajectory under various scenarios.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $10.42 with a min of $7.30 and a max of $16.12. The forecast implies a ROI of 58.6 and a Bullish sentiment.
Long-term forecasts show a bullish path with substantial upside by 2040 and 2050 (average prices of $17.88 and $40.98 with ROIs of 172.1% and 523.8%), but near-term forecasts for 2026–2027 are Neutral and the current price is $6.57 with Bearish near-term momentum.
The 2050 forecast shows an average price of $40.98 and a max of $84.16 with a ROI of 523.8%, indicating that a $50 level could occur in the forecast horizon, though it is not guaranteed.
The current price is $6.57, with a market capitalization of $437.78M and a rank of 3140.
The 30-day range is $5.20 to $8.29, RSI is 40, and the sentiment is Bearish. The SMA50 is $7.28 and the SMA200 is $8.80, with support at $5.91 and resistance at $8.29.
Fulcrum Therapeutics, Inc. Community Discussion
0Share your Fulcrum Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.